Compare Clorox Co (CLX) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Clorox Co vs Stryker Corporation — how do they compare? Clorox Co trades at $97 (market cap $11.46B), while Stryker Corporation trades at $316.44 (market cap $119.25B). The key difference: Stryker Corporation is far larger — about 10.4× Clorox Co's market cap, and Clorox Co pays the higher dividend (5.23%). Which is the better fit depends on your goals.
| CLX | SYK | |
|---|---|---|
Market Cap | $11.46B | $119.25B |
Sector | Consumer Staples | Technology |
52-Week High | $131.43 | $403.53 |
52-Week Low | $86.12 | $282.58 |
Enterprise Value | $14.76B | $131.01B |
Dividend Yield | 5.23% | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CLX trades at $95.05, down 1.56% on the day, with technical indicators showing a bearish trend. The company reported strong Q1 2026 earnings beat with EPS of $1.64 versus $1.55 expected, though revenue trends remain flat. Recent corporate developments include a simplified operating structure announcement and CEO transition for health reasons. The stock offers a 5%+ dividend yield with recent H1-26 dividend of $1.24 payable May 2026.
CLX presents a mixed outlook with attractive dividend income but faces growth challenges. The 8.7% upside to consensus price target of $103.38 suggests moderate potential, though high P/B ratio of 41.4 and declining revenue projections for 2026 warrant caution. Key risks include execution of new operating structure and competitive pressures in consumer staples.
Stryker (SYK) trades at $331.45, up 0.51% today, with strong analyst support (74% buy ratings) and a consensus price target of $388.44. The stock shows bullish technical signals despite a recent Q1 2026 earnings miss attributed to a temporary cyber disruption. Fundamentals remain solid with 2025 revenue of $25.12B, net income margin of 13.21%, and robust cash flow generation of $5.04B from operations.
Outlook remains positive with maintained full-year guidance and healthy end-market demand. Investment opportunity lies in the valuation discount to historical averages and innovation-driven growth. Key risks include cybersecurity vulnerabilities and competitive pressures in the medtech sector. The stock offers potential upside of 17% to consensus target with dividend stability as a Dividend Aristocrat.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
